Evidence map›Paper›PMID 40858915›Full record

ArticleAnnals of intensive care2025

Urinary 3-methylhistidine as a potential biomarker for sepsis-associated acute kidney injury: multidimensional metabolomics analysis in mice and human.

Xibo Wang, Pengfei Huang, Yinghao Luo, Yu Xin, Yue Li, Lifeng Shen, Yanqi Liu, Yang Zhou, Yuxin Zhang, Qianqian Zhang and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Xibo Wang *Departments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Pengfei Huang *Departments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Yinghao Luo *Departments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Yu Xin *Departments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Yue Li *Department of Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang Province, China.
Lifeng ShenDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Yanqi LiuDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Yang ZhouDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Yuxin ZhangDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Qianqian ZhangDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Dawei WangDepartment of Critical Care Medicine, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Feiyu LuanDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Weiting ZhangDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Mengyao YuanDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Yuhan LiuDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Fengye LiuDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Nan ZhangDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Jinyuan WuDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Tao WuDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Xuan WangDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Yuping BaiDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Mingyan ZhaoDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China. mingyan1970@126.com.
Changsong WangDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China. changsongwang@hrbmu.edu.cn.
Kaijiang YuDepartments of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150001, Heilongjiang, China. drkaijiang@163.com.

Funding

National Natural Science Foundation of China 82430069National Natural Science Foundation of China 82472198
6 · The paper itself

Abstract

backgroundSepsis-associated acute kidney injury (SA-AKI) is strongly associated with increased mortality in critical patients. The early detection of SA-AKI is crucial for clinical intervention. This study aims to integrate multiple metabolomics data related to SA-AKI to identify and validate novel metabolic markers.

methodsReal-time glomerular filtration rate (RT-GFR) measurement was adopted to establish SA-AKI mice. Untargeted metabolomics sequencing was performed on SA-AKI mice renal tissue (Control-LPS-8 h-LPS-24 h, N = 4) and urine samples (Control group vs. LPS-24 h group, N = 6). Time series analysis and random forest algorithm were employed to identify key metabolic molecule. Subsequently, renal spatiotemporal metabolomics was used to explore the specific distribution of key molecule. Eventually, a clinical cohort (20 healthy volunteers vs. 30 sepsis patients vs. 45 SA-AKI patients) urine quantitative metabolomic analysis was carried out to validate it as a biomarker and construct a diagnostic model via logistic regression (LR).

resultsForty-two key renal metabolites and top fifty urinary metabolites were determined through multidimensional metabolomics study of SA-AKI mice. Urinary 3-Methylhistidine (3-MH) was charactered as a potential biomarker. The distribution of 3-MH increased in collecting ducts through renal spatiotemporal metabolomics sequencing. Then, we recruited 95 urine samples to validate its diagnostic performance (AUC = 0.86, 95% CI 0.77-0.95) and its role as an independent predictive factor for SA-AKI (OR = 0.21, 95% CI: 0.05-0.84, p < 0.05). Ultimately, a diagnostic model combined urinary 3-MH with clinical variables was constructed to identify SA-AKI (AUC = 0.89, 95% CI 0.74-1.00).

conclusionsWe proposed that urinary 3-Methylhistidine has potential diagnostic value for SA-AKI screening. Future studies will focus on its performance in other clinical populations to comprehensively evaluate its diagnostic role.

Indexed as

3-MethylhistidineDiagnostic biomarkersMetabolomeSepsisSepsis-associated acute kidney injuryUrine

Identifiers

PMID40858915
PMCPMC12380662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.